

Stereoselective Synthesis of Novel (\pm)-*trans*-Dihydronarciclasine Analogues: Preparation of a Pivotal Intermediate Containing Two Methoxy Substituents

Balázs Lévai¹, Gábor Varró², András Simon³, László Hegedűs¹, István Kádas^{1*}

¹ Department of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3., H-1111 Budapest, Hungary

² Gedeon Richter Plc., Gyömrői út 19-21., H-1103 Budapest, Hungary

³ Department of Inorganic and Analytical Chemistry, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3., H-1111 Budapest, Hungary

* Corresponding author, e-mail: kadas.istvan@vbk.bme.hu

Received: 10 May 2022, Accepted: 11 August 2022, Published online: 09 January 2023

Abstract

An efficient stereoselective synthesis of a pivotal intermediate, a cyclic allyl alcohol derivative containing two methoxy groups [(\pm)-**22**], using for the preparation of (\pm)-*trans*-dihydronarciclasine analogues was elaborated starting from easily available and inexpensive methyl gallate. This new synthetic route consists of 17 reaction steps, and provides an opportunity to obtain the wanted alkaloid derivative containing an additional methoxy group at position 11, in the ring A of the phenanthridone scaffold.

Keywords

alkaloids, phenanthridone scaffold, stereoselective synthesis

1 Introduction

Although the phenanthridone alkaloids are a relatively little group of the *Amaryllidaceae* alkaloids, several highly potent anticancerous compounds belong to this group, from which the most active ones are narciclasine (**1**), *trans*-dihydronarciclasine (**2**), pancratistatin (**3**) and *trans*-dihydrolycoricidine (**4**) [1] (Fig. 1).

In the nature, these alkaloids can be found in the species of genus *Narcissus*, *Zephyranthes* and *Hymenocallis*, but their concentrations are very low in these herbs, thus their biological investigations proved to be difficult [2–6]. Therefore, their chemical syntheses became necessary to obtain them in appropriate amounts. After their first total syntheses [7–10], a relatively large number of modified new ones was evaluated in the next two decades [1]. In parallel with these syntheses of the natural alkaloids, their new analogues were also prepared providing an opportunity to elucidate their structure–activity relationships (SAR) [11].

After developing new enantioselective total syntheses of the *ent*-forms of *trans*-dihydrolycoricidine [12] and *trans*-dihydronarciclasine [13] by us, the preparation of novel analogues of these compounds were also




Fig. 1 Structures of the typical *Amaryllidaceae* alkaloids with high anticancerous activity (1–4)

elaborated [14–16]. Since the literature syntheses of the abovementioned analogues were performed by changing the substituents of ring B or C, while the ring A remained untouched, we focused on the modification of the ring A of the phenanthridone scaffold.

Herein, connecting to our previous works, we report an efficient stereoselective synthesis of a pivotal intermediate, a cyclic allyl alcohol derivative containing two methoxy groups in ring A, which can be used for the preparation of new (\pm)-*trans*-dihydranarciclasine analogues.

It seemed to be the best choice for the starting material of our new synthesis was apiolealdehyde (4,7-dimethoxybenzo[*d*][1,3]dioxole-5-carbaldehyde (**5**), which can easily be synthesised from apiole (5-allyl-4,7-dimethoxybenzo[*d*][1,3]dioxole), a naturally occurring compound, the main constituent of parsley oil [17]. Due to the high price of apiole, however, another starting compound was chosen for the synthesis of apiolealdehyde: the relatively inexpensive methyl gallate (**6**).

2 Experimental

2.1 Materials and methods

All reagents are commercially available from Merck. Melting points were measured on a Büchi 510 apparatus using a certified mercury thermometer (ASTM 2C). NMR spectra were recorded on a Bruker AV-300 or DRX-500 instrument operating at 300 or 500 MHz, in CDCl₃ and DMSO-*d*₆, respectively. IR spectra were recorded on a Bruker Tensor 37 FT-IR spectrophotometer. Precoated silica gel plates (Merck 60 F₂₅₄) were used for analytical TLC and Kieselgel 60 for column chromatography.

2.2 Preparation of methyl 2-ethoxy-7-hydroxybenzo[*d*][1,3]dioxole-5-carboxylate (**7**)

To a solution of **6** (9.2 g, 50.0 mmol) in toluene (400 cm³) were added Amberlite® IR-120 (0.26 g), a strongly acidic cation exchange resin, and triethyl orthoformate (25 cm³, 0.50 mmol), then the reaction mixture was stirred for 8 h under reflux. Next, the mixture was filtered, and the filtrate was evaporated *in vacuo* to afford **7** (11.93 g, 99%) as a white solid. M.p. 91–92 °C (Lit. m.p. compound **7** decomposes before melting [18]); ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.42 (d, *J* = 1.9 Hz, 1H, 4-H_{Ar}), 7.20 (d, *J* = 1.9 Hz, 1H, 6-H_{Ar}), 6.97 (s, 1H, OCHO), 6.00 (br s, 1H, OH), 3.90 (s, 3H, COOCH₃), 3.70 (q, *J* = 4.8 Hz, 2H, OCH₂CH₃), 1.29 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃); ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 166.9 (COOCH₃), 147.1 (3a-C_{Ar}), 138.7 (7-C_{Ar}), 137.1 (7a-C_{Ar}), 124.0 (5-C_{Ar}), 120.1 (OCHO), 114.0 (6-CH_{Ar}), 102.7 (4-CH_{Ar}), 59.7 (OCH₂CH₃), 52.4 (COOCH₃), 14.7 (OCH₂CH₃); IR (KBr) 3351, 1709, 1618, 1438, 1316, 1254, 1081, 1038, 765 cm⁻¹.

2.3 Preparation of methyl 2-ethoxy-7-methoxybenzo[*d*][1,3]dioxole-5-carboxylate (**8**)

To a solution of **7** (8.93 g, 37.2 mmol) in acetone (140 cm³) were added anhydrous K₂CO₃ (5.14 g, 37.2 mmol) and methyl iodide (6.00 cm³, 8.66 g, 61.0 mmol). The reaction mixture was stirred for 8 h under reflux. The insoluble solid was filtered and washed with acetone. The filtrate was evaporated *in vacuo* to give **8** (9.23 g, 98%) as a white solid. M.p. 47–48 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.36 (d, *J* = 2.2 Hz, 1H, 4-H_{Ar}), 7.27 (d, *J* = 2.2 Hz, 1H, 6-H_{Ar}), 6.97 (s, 1H, OCHO), 3.96 (s, 3H, OCH₃), 3.89 (s, 3H, COOCH₃), 3.77 (q, *J* = 4.8 Hz, 2H, OCH₂CH₃), 1.29 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃); ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 166.4 (COOCH₃), 147.0 (3a-C_{Ar}), 138.0 (7-C_{Ar}), 137.5 (7a-C_{Ar}), 124.3 (5-C_{Ar}), 122.7 (OCHO), 109.7 (6-CH_{Ar}), 103.5 (4-CH_{Ar}), 59.7 (OCH₂CH₃), 56.6 (OCH₃), 52.2 (COOCH₃), 14.8 (OCH₂CH₃); IR (KBr) 2983, 1723, 1643, 1438, 1246, 1095, 924, 762 cm⁻¹.

2.4 Preparation of methyl 3,4-dihydroxy-5-methoxybenzoate (**9**)

To a solution of **8** (13.7 g, 53.9 mmol) in MeOH (70 cm³) was added 2M aqueous HCl solution (95 cm³) dropwise within 1 h. The reaction mixture was stirred at room temperature for additional 4 h, then the solvent was removed *in vacuo*. The residue was dissolved in ethyl acetate (130 cm³), and kept at 0–5 °C for 24 h. The precipitated white by-product (a gallic acid derivate) was removed by filtration, and the filtrate was evaporated *in vacuo* to afford the crude product which was recrystallized from MeOH to give **9** (9.60 g, 87%) as a pale yellow solid. M.p. 108–109 °C (Lit. m.p. 110–111 °C [19]); ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.37 (d, *J* = 2.2 Hz, 1H, 2-H_{Ar}), 7.23 (d, *J* = 2.2 Hz, 1H, 6-H_{Ar}), 5.88 (br s, 1H, 4-OH), 5.49 (br s, 1H, 3-OH), 3.95 (s, 3H, OCH₃), 3.90 (s, 3H, COOCH₃); ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 167.6 (COOCH₃), 147.2 (5-C_{Ar}), 144.2 (3-C_{Ar}), 138.5 (4-C_{Ar}), 120.4 (1-C_{Ar}), 110.8 (2-CH_{Ar}), 104.9 (6-CH_{Ar}), 56.0 (OCH₃), 51.9 (COOCH₃); IR (KBr) 3382, 1708, 1593, 1506, 1436, 1243, 1161, 1058, 1000, 964, 726 cm⁻¹.

2.5 Preparation of methyl 2-bromo-3,4-dihydroxy-5-methoxybenzoate (**10**)

To a solution of **9** (3.05 g, 15.4 mmol) in CHCl₃ (77 cm³) was added 1,3-dibromo-5,5-dimethylhydantoin (2.24 g, 7.83 mmol, DBDMH) in small portions within 2.5 h. After stirring the reaction mixture at room temperature for 22 h, a 10% aqueous Na₂S₂O₄ solution (50 cm³) was added to it. After 30 min additional stirring, the phases were separated

and the organic one was dried over Na_2SO_4 . The solvent was removed *in vacuo* to yield **10** (3.90 g, 92%) as pale yellow crystals. M.p. 124–125 °C (Lit. m.p. 141 °C [20]); ^1H NMR (300 MHz, CDCl_3) δ (ppm) 7.19 (s, 1H, 6- H_{Ar}), 5.98 (bs, 1H, 4-OH), 5.84 (bs, 1H, 3-OH), 3.98 (s, 3H, OCH_3), 3.94 (s, 3H, COOCH_3); ^{13}C NMR (75 MHz, CDCl_3) δ (ppm) 165.9 (COOCH_3), 145.7 (5- C_{Ar}), 141.4 (3- C_{Ar}), 136.7 (4- C_{Ar}), 121.8 (1- C_{Ar}), 107.1 (2- C_{Ar}), 103.3 (6- CH_{Ar}), 56.4 (OCH_3), 52.3 (COOCH_3); IR (KBr) 3461, 3341, 1717, 1601, 1429, 1292, 1210, 1101, 1018, 923, 776 cm^{-1} .

2.6 Preparation of methyl 4-bromo-7-methoxybenzo[d][1,3]dioxole-5-carboxylate (11)

To a solution of **10** (5.82 g, 21.0 mmol) in DMF (162 cm^3) were added anhydrous KF (6.14 g, 0.11 mol) and CH_2Br_2 (5 cm^3 , 12.4 g, 71.3 mmol). The reaction mixture was stirred at 85–90 °C under an Ar atmosphere for 12 h. After cooling it to room temperature, the solvent was removed *in vacuo*, and water (20 cm^3) was added to the residue. It was extracted with Et_2O (4 \times 20 cm^3), then the combined organic phase was washed with brine and dried over Na_2SO_4 . The solvent was also removed *in vacuo* to afford **11** (4.53 g, 75%) as a yellow solid. M.p. 92–93 °C (Lit. m.p. 103–104 °C [21]); ^1H NMR (300 MHz, CDCl_3) δ (ppm) 7.27 (s, 1H, 6- H_{Ar}), 6.14 (s, 2H, OCH_2O), 3.96 (s, 3H, OCH_3), 3.94 (s, 3H, COOCH_3); ^{13}C NMR (75 MHz, CDCl_3) δ (ppm) 165.4 (COOCH_3), 148.0 (3a- C_{Ar}), 142.2 (7- C_{Ar}), 138.3 (7a- C_{Ar}), 124.2 (5- C_{Ar}), 112.4 (6- CH_{Ar}), 102.4 (4- C_{Ar}), 94.4 (OCH_2O), 56.8 (OCH_3), 52.3 (COOCH_3); IR (KBr) 1724, 1433, 1324, 1248, 1175, 1107, 1041, 935 cm^{-1} .

2.7 Preparation of 4-bromo-7-methoxybenzo[d][1,3]dioxole-5-carboxylic acid (12)

To a solution of **11** (5.68 g, 19.6 mmol) in *i*-PrOH (43 cm^3) was added KOH (1.24 g, 22.1 mmol) in water (1 cm^3), and it was heated to reflux and stirred for 6 h. It was cooled below 10 °C and acidified with concentrated HCl (3 cm^3) to pH = 2. The precipitated crude product was filtered and dried, then it was recrystallized from *i*-PrOH to give **12** (4.23 g, 79%) as a white solid. M.p. 236–237 °C (Lit. m.p. 242–243 °C [22]); ^1H NMR (300 MHz, CDCl_3) δ (ppm) 12.60 (s, 1H, COOH), 7.44 (s, 1H, 6- H_{Ar}), 6.17 (s, 2H, OCH_2O), 3.96 (s, 3H, OCH_3); ^{13}C NMR (75 MHz, CDCl_3) δ (ppm) 167.2 (COOH), 147.5 (3a- C_{Ar}), 144.8 (7- C_{Ar}), 138.2 (7a- C_{Ar}), 126.8 (5- C_{Ar}), 106.8 (6- CH_{Ar}), 102.8 (4- C_{Ar}), 102.0 (OCH_2O), 56.5 (OCH_3); IR (KBr) 2940, 2840, 1868, 1623, 1432, 1346, 1167, 1110, 1042, 932 cm^{-1} .

2.8 Preparation of apiolic acid (4,7-dimethoxybenzo[d][1,3]dioxole-5-carboxylic acid) (13)

To a solution of freshly prepared NaOMe (13.5 g, 0.25 mol) in MeOH (93 cm^3) were added compound **12** (4.59 g, 16.7 mmol) and Cu (0.30 g, 4.7 mmol). The reaction mixture was heated to reflux and stirred for 30 h. The precipitated material was filtered and washed thoroughly with hot water (150 cm^3). The filtrate was acidified with concentrated H_2SO_4 to pH = 2, then kept at 0–5 °C for 24 h. The yellowish, precipitated crude product was also filtered and dried, then it was recrystallized from EtOH to afford **13** (3.64 g, 82%) as a white solid. M.p. 185–189 °C (Lit. m.p. 173–174 °C [22]); ^1H NMR (300 MHz, CDCl_3) δ (ppm) 12.40 (s, 1H, COOH), 7.41 (s, 1H, 6- H_{Ar}), 6.13 (s, 2H, OCH_2O), 3.50 (s, 6H, 2 \times OCH_3); ^{13}C NMR (75 MHz, CDCl_3) δ (ppm) 166.6 (COOH), 141.9 (3a- C_{Ar}), 141.0 (7- C_{Ar}), 140.1 (4- C_{Ar}), 140.0 (7a- C_{Ar}), 118.3 (5- C_{Ar}), 106.7 (6- CH_{Ar}), 102.1 (OCH_2O), 62.0 (4- OCH_3), 56.5 (7- OCH_3); IR (KBr) 2844, 1865, 1633, 1429, 1326, 1168, 1070, 857 cm^{-1} .

2.9 Preparation of 4,7-dimethoxybenzo[d][1,3]dioxole (14)

A solution of **13** (1.20 g, 5.31 mmol) in *N,N*-dimethylaniline (4 cm^3 , DMA) was heated to reflux and stirred until the gas evolving (CO_2) ceased (5 h). Then, the reaction mixture was cooled to room temperature and a 10% aqueous NaOH solution (10 cm^3) was added. After its extracting with CH_2Cl_2 (10 cm^3) and evaporating the organic solvent, the crude product was distilled *in vacuo* to afford **14** (0.44 g, 46%) as a light brown oil, which was spontaneously solidified. B.p. 122–124 °C/0.3 Torr; m.p. 75–76 °C (Lit. m.p. 76.5–77.5 °C [23]); ^1H NMR (300 MHz, CDCl_3) δ (ppm) 6.85 (s, 2H, 5- and 6- H_{Ar}), 5.96 (s, 2H, OCH_2O), 3.81 (s, 6H, 2 \times OCH_3); ^{13}C NMR (75 MHz, CDCl_3) δ (ppm) 141.1 (4- and 7- OCH_3), 130.6 (3a- and 7a- C_{Ar}), 110.3 (5- and 6- CH_{Ar}), 100.0 (OCH_2O), 57.1 (2 \times OCH_3); IR (KBr) 3073, 2838, 1732, 1514, 1466, 1309, 1108, 1083, 953 cm^{-1} .

2.10 Preparation of apiolealdehyde (4,7-dimethoxybenzo[d][1,3]dioxole-5-carbaldehyde) (5)

To a mixture of POCl_3 (0.40 cm^3 , 0.66 g, 4.28 mmol) and *N*-methylformanilide (0.40 cm^3 , 0.44 g, 3.24 mmol, NMFA) was added compound **14** (0.45 g, 2.50 mmol). The reaction mixture was stirred at room temperature for 3 h, and it was left for standing overnight. Then, water (10 cm^3) was added to it, and it was extracted with Et_2O (3 \times 10 cm^3). The combined organic phase was washed with saturated NaHCO_3 solution and dried over Na_2SO_4 . After evaporating the

solvent, the crude product was purified by column chromatography (hexane–EtOAc, 2:1) to give **5** (0.29 g, 59%) as a white solid. M.p. 99–101 °C (Lit. m.p. 99–101 °C [24]); ¹H NMR (300 MHz, CDCl₃) δ (ppm) 10.24 (s, 1H, CHO), 7.08 (s, 1H, 6-H_{Ar}), 6.10 (s, 2H, OCH₂O), 4.06 (s, 3H, 4-OCH₃), 3.89 (s, 3H, 7-OCH₃); ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 183.1 (CHO), 155.5 (3a-C_{Ar}), 147.7 (4-C_{Ar}), 147.4 (7-C_{Ar}), 147.2 (7a-C_{Ar}), 128.8 (5-C_{Ar}), 101.3 (6-CH_{Ar}), 98.0 (OCH₂O), 56.0 (4-OCH₃), 51.8 (7-OCH₃); IR (KBr) 2907, 2859, 1659, 1632, 1593, 1238, 1146, 1071, 639 cm⁻¹.

2.11 Preparation of 4',7'-dimethoxy-5'-(2-nitrovinyl)-benzo[d][1,3]dioxole (**15**)

To a solution of **5** (0.85 g, 4.04 mmol) in acetic acid (6 mL) containing NH₄OAc (0.74 g, 9.60 mmol) was added nitromethane (1.5 mL, 1.71 g, 28.0 mmol). The reaction mixture was heated to reflux and stirred for 2.5 h. Then it was cooled down to room temperature and ice-cold water (20 mL) was added. The mixture was kept at 0–5 °C for 30 min. The precipitated orange crystals were filtered and dried to afford **15** (0.84 g) in 82% yield. M.p. 157–159 °C (Lit. m.p. 166–167 °C [25]); ¹H NMR (500 MHz, CDCl₃) δ (ppm) 8.04 (d, *J* = 13.5 Hz, 1H, CH=CHNO₂), 7.76 (d, *J* = 13.5 Hz, 1H, CH=CHNO₂), 6.64 (s, 1H, 6'-H_{Ar}), 6.08 (s, 2H, OCH₂O), 4.06 (s, 3H, 4'-OCH₃), 3.90 (s, 3H, 7'-OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 141.4 (3'a-C_{Ar}), 139.9 (7'-C_{Ar}), 139.8 (4'-C_{Ar}), 137.6 (CH=CHNO₂), 136.0 (7'a-C_{Ar}), 134.5 (CH=CHNO₂), 118.5 (5'-C_{Ar}), 106.8 (6'-CH_{Ar}), 102.1 (OCH₂O), 61.5 (4'-OCH₃), 56.5 (7'-OCH₃); IR (KBr) 3093, 1618, 1593, 1487, 1457, 1431, 1310, 1236, 1070, 967 cm⁻¹.

2.12 Preparation of (±)-4-(4',7'-dimethoxybenzo[d][1,3]dioxol-5'-yl)-5-nitropentan-2-one [(±)-**16**]

To a solution of **15** (0.84 g, 3.32 mmol) and L-proline (0.095 g, 0.83 mmol) in DMSO (30 mL) was added acetone (11.5 mL, 156 mmol, 9.09 g), and the reaction mixture was stirred at room temperature for 44 h. Then saturated NH₄Cl solution (36 mL) was added, and after a 5 min stirring water (14 mL) was also poured into the reaction mixture. It was then extracted with CHCl₃ (3 × 22 mL), and the combined organic phase was washed with water and brine, then dried over Na₂SO₄. After evaporating the solvent, the crude product was recrystallized from MeOH to give (±)-**16** (1.00 g, 97%) as a light brown solid. M.p. 82–84 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm) 6.29 (s, 1H, 6'-H_{Ar}), 5.97 (s, 2H, OCH₂O), 4.68 (d, 2H, *J* = 7.2 Hz, CH₂NO₂), 4.09 (p, *J* = 7.2 Hz, 1H, 4-CH), 3.98 (s, 3H, 7'-OCH₃), 3.85 (s, 3H, 4'-OCH₃), 2.92 (d, *J* = 6.6 Hz, 2H,

CH₂CO), 2.14 (s, 3H, COCH₃); ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 206.6 (CO), 142.4 (3'a-C_{Ar}), 140.0 (7'-C_{Ar}), 139.6 (4'-C_{Ar}), 138.3 (7'a-C_{Ar}), 127.7 (5'-C_{Ar}), 106.5 (6-CH_{Ar}), 101.6 (OCH₂O), 76.7 (CH₂NO₂), 60.8 (4'-OCH₃), 56.5 (7'-OCH₃), 43.4 (CH₂CO), 34.7 (4-CH), 30.3 (COCH₃); IR (KBr) 3435, 2912, 1711, 1509, 1368, 1142, 1070, 1003, 966, 858 cm⁻¹.

2.13 Preparation of (±)-3-(4',7'-dimethoxybenzo[d][1,3]dioxol-5'-yl)-5-hydroxy-4-nitrocyclohexan-1-one [(±)-**17**]

To a solution of freshly prepared NaOMe (0.80 g, 14.8 mmol) in abs. Et₂O (10 cm³) were added freshly distilled ethyl formate (2.0 cm³, 1.83 g, 24.8 mmol) and subsequently compound (±)-**16** (1.00 g, 3.21 mmol). The reaction mixture was stirred at room temperature for 20 h, then water (7 cm³) was slowly added to it under cooling, and the phases were separated. The organic one was extracted with water (3 × 5 cm³), then the combined aqueous phase was acidified with acetic acid to pH = 4. The precipitated pale yellow solid was filtered, washed with water and dried to afford (±)-**17** (0.60 g) in 55% yield. M.p. 143–145 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ (ppm) 6.74 (s, 1H, 6'-H_{Ar}), 6.00 (s, 2H, OCH₂O), 4.70 (d, *J* = 7.8 Hz, 1H, CHNO₂), 4.38 (s, 1H, OH), 4.30 (m, 1H, CHOH), 4.11 (m, 1H, 3-CH), 3.86 (s, 3H, 7'-OCH₃), 3.78 (s, 3H, 4'-OCH₃), 2.56 (m, 2H, 2-CH₂), 2.44 (m, 2H, 6-CH₂); ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 207.6 (CO), 142.1 (3'a-C_{Ar}), 139.9 (7'-C_{Ar}), 138.9 (4'-C_{Ar}), 138.2 (7'a-C_{Ar}), 126.6 (5'-C_{Ar}), 106.2 (6'-CH_{Ar}), 101.6 (OCH₂O), 87.0 (CH₂NO₂), 69.7 (CHOH), 60.5 (4'-OCH₃), 56.4 (7'-OCH₃), 44.7 (6-CH₂), 44.6 (2-CH₂), 39.7 (3-CH); IR (KBr) 3354, 2360, 1716, 1551, 1507, 1456, 1353, 1138, 1070, 1051, 982 cm⁻¹.

2.14 Preparation of (±)-9-(4',7'-dimethoxybenzo[d][1,3]dioxol-5'-yl)-8-nitro-1,4-dioxaspiro[4.5]decan-7-ol [(±)-**18**]

To a solution of anhydrous oxalic acid (2.24 g, 24.9 mmol) in freshly distilled MeCN (37 cm³) were added ethylene glycol (6.4 cm³, 7.12 g, 115 mmol) and compound (±)-**17** (0.90 g, 2.65 mmol). The reaction mixture was stirred at room temperature for 110 h, then it was poured into a cooled saturated NaHCO₃ solution (113 cm³), and pH was kept above 8. The precipitated light brown solid was collected by filtration, washed with saturated NaHCO₃ solution (15 cm³) and water (2 × 15 cm³), then dried to give (±)-**18** (0.78 g) in 77% yield. M.p. 140–142 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm) 6.30 (s, 1H, 6'-H_{Ar}), 6.02 (s, 2H, OCH₂O), 5.10–5.06 (m, 1H, CHNO₂), 4.88 (s, 1H, OH), 4.80–4.76 (m, 1H, CHOH), 4.20–4.16 (m, 1H, 9-CH), 4.04 (s, 3H, 7'-OCH₃),

4.02 (s, 3H, 4'-OCH₃), 3.96–3.91 (m, 4H, OCH₂CH₂O), 2.30–1.80 (m, 4H, 6-CH₂ and 10-CH₂); ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 142.3 (3'a-C_{Ar}), 140.7 (4'-C_{Ar}), 140.1 (7'-C_{Ar}), 138.3 (7'a-C_{Ar}), 128.8 (5'-C_{Ar}), 107.2 (6'-CH_{Ar}), 106.9 (5-C), 101.6 (OCH₂O), 88.1 (CH₂NO₂), 69.9 (CHOH), 64.2 (OCH₂CH₂O), 60.3 (4'-OCH₃), 56.3 (7'-OCH₃), 40.1 (6-CH₂), 38.7 (10-CH₂), 38.0 (9-CH); IR (KBr) 3462, 2942, 1551, 1435, 1190, 1064, 952 cm⁻¹.

2.15 Preparation of (±)-8-amino-9-(4',7'-dimethoxybenzo[d][1,3]dioxol-5'-yl)-1,4-dioxaspiro[4.5]decan-7-ol [(±)-19]

Over a 10% Pd/C catalyst (Selcat Q, 0.12 g) compound (±)-18 (0.40 g, 1.04 mmol) was hydrogenated in MeOH (50 cm³) in a 250 cm³ stainless steel autoclave equipped with a magnetic stirrer (stirring speed: 1100 rpm). The reduction was carried out at 12 bar and 80 °C for 7 h. After the hydrogen uptake was finished, the catalyst was removed by filtration and the filtrate was concentrated *in vacuo* to afford (±)-19 (0.35 g, 95%) as a pale yellow solid. M.p. 92–94 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm) 6.31 (s, 1H, 6-H_{Ar}), 5.98 (s, 2H, OCH₂O), 4.58 (s, 1H, OH), 4.22–4.18 (m, 1H, 9-CH), 4.02 (s, 3H, 7'-OCH₃), 3.98 (s, 3H, 4'-OCH₃), 3.95–3.92 (m, 4H, OCH₂CH₂O), 3.80–3.76 (m, 1H, CHOH), 2.39 (br s, 2H, NH₂), 2.30–1.80 (m, 4H, 6-CH₂ and 10-CH₂); ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 142.7 (3'a-C_{Ar}), 140.3 (7'-C_{Ar}), 139.7 (4'-C_{Ar}), 138.4 (7'a-C_{Ar}), 128.9 (5'-C_{Ar}), 106.7 (5-C), 106.4 (6'-CH_{Ar}), 101.6 (OCH₂O), 70.3 (CHOH), 64.2 (OCH₂CH₂O), 60.5 (4'-OCH₃), 59.9 (CHNH₂), 56.3 (7'-OCH₃), 40.0 (6-CH₂), 38.9 (9-CH), 37.5 (10-CH₂); IR (KBr) 3445, 2936, 1506, 1455, 1431, 1137, 1062, 984 cm⁻¹.

2.16 Preparation of (±)-7-(4',7'-dimethoxybenzo[d][1,3]dioxol-5'-yl)-9-hydroxy-1,4-dioxaspiro[4.5]decan-8-yl carbamic acid methyl ester [(±)-20]

Half of the required methyl chloroformate (0.07 cm³, 85.4 mg, 0.90 mmol), 3% aqueous NaOH solution (2 cm³), and subsequently the other half of methyl chloroformate (0.07 cm³, 85.4 mg, 0.90 mmol) were added to a solution of (±)-19 (0.30 g, 0.85 mmol) in THF (7.4 cm³). The reaction mixture was stirred rigorously at room temperature for 51 h, then it was poured into water (25 cm³) and extracted with EtOAc (4 × 20 cm³). The combined organic layer was washed with brine, dried over Na₂SO₄, and the solvent was evaporated *in vacuo* to give (±)-20 (0.30 g, 86%) as a light brown solid. M.p. 153–157 °C; ¹H NMR (300

MHz, CDCl₃) δ (ppm) 7.48 (s, 1H, NHCOOCH₃), 6.40 (s, 1H, 6'-H_{Ar}), 5.98 (s, 2H, OCH₂O), 4.33 (s, 1H, OH), 4.25 (td, *J* = 11.3 and 4.3 Hz, 1H, CHNHCOOCH₃), 4.09–4.05 (m, 1H, CHOH), 3.98 (s, 3H, 4'-OCH₃), 3.96 (s, 3H, 7'-OCH₃), 3.90–3.82 (m, 4H, OCH₂CH₂O), 3.51–3.47 (m, 1H, 7-CH), 2.20–2.00 (m, 4H, 6-CH₂ and 10-CH₂), 1.91 (s, 3H, NHCOOCH₃); ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 172.9 (NHCOOCH₃), 142.7 (3'a-C_{Ar}), 140.1 (7'-C_{Ar}), 139.8 (4'-C_{Ar}), 138.4 (7'a-C_{Ar}), 130.5 (5'-C_{Ar}), 107.9 (5-C), 106.6 (6'-CH_{Ar}), 101.6 (OCH₂O), 70.2 (CHOH), 64.3 (OCH₂CH₂O), 60.5 (4'-OCH₃), 56.3 (7'-OCH₃), 56.2 (CHNHCOOCH₃), 38.8 (6-CH₂), 38.7 (9-CH), 36.7 (10-CH₂), 23.0 (NHCOOCH₃); IR (KBr) 3477, 3355, 2927, 1723, 1638, 1541, 1516, 1450, 1319, 1129, 1073, 914 cm⁻¹.

2.17 Preparation of (±)-6-(4',7'-dimethoxybenzo[d][1,3]dioxol-5'-yl)-4-oxocyclohex-2-en-1-yl carbamic acid methyl ester [(±)-21]

A solution of (±)-20 (0.30 g, 0.73 mmol) and *p*-TsOH (0.25 g, 1.31 mmol) in acetone (17 cm³) was heated to reflux and stirred for 2.5 h. After cooling to room temperature, it was poured into saturated NaHCO₃ solution (34 cm³) and extracted with CHCl₃ (4 × 20 cm³). The combined organic phase was washed with water and brine, dried over Na₂SO₄, and the solvent was evaporated *in vacuo* to afford (±)-21 (0.26 g, 97%) as a light brown solid. M.p. 127–130 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.43 (s, 1H, NHCOOCH₃), 7.32 (s, 1H, 6'-H_{Ar}), 7.00 (d, *J* = 9.8 Hz, 1H, CH=CHCO), 6.98 (d, *J* = 9.8 Hz, 1H, CH=CHCO), 6.96 (s, 2H, OCH₂O), 4.72–4.66 (m, 1H, CHNHCOOCH₃), 3.99 (s, 3H, 7'-OCH₃), 3.96 (s, 3H, 4'-OCH₃), 3.52–3.46 (m, 1H, 6-CH), 2.44–2.40 (m, 2H, 5-CH₂), 1.93 (s, 3H, HNCOOCH₃); ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 197.4 (4-CO), 172.6 (NHCOOCH₃), 142.0 (3'a-C_{Ar}), 140.0 (7'-C_{Ar}), 139.3 (CH=CHCO), 138.3 (4'-C_{Ar}), 138.2 (7'a-C_{Ar}), 130.5 (5'-C_{Ar}), 129.7 (CH=CHCO), 106.4 (6'-CH_{Ar}), 101.6 (OCH₂O), 60.6 (4'-OCH₃), 56.4 (7'-OCH₃), 49.9 (CHNHCOOCH₃), 41.3 (5-CH₂), 39.6 (6-CH), 22.8 (NHCOOCH₃); IR (KBr) 3420, 2935, 1717, 1683, 1556, 1507, 1433, 1138, 1062, 953 cm⁻¹.

2.18 Preparation of (±)-6-(4',7'-dimethoxybenzo[d][1,3]dioxol-5'-yl)-4-hydroxycyclohex-2-en-1-yl carbamic acid methyl ester [(±)-22]

A solution of (±)-21 (0.26 g, 0.71 mmol) and CaCl₂ (0.38 g, 3.42 mmol) in abs. MeOH (8 cm³) was stirred at room temperature for 30 min. Then, NaBH₄ (0.14 g, 3.78 mmol) was added in one portion and the reaction mixture was further stirred at room temperature for 19 h. Thereafter, it

was poured into water (37 cm³) and extracted with EtOAc (4 × 25 cm³). The combined organic layer was washed with water and brine, dried over Na₂SO₄, and the solvent was evaporated *in vacuo*. The crude product was purified by preparative TLC (CHCl₃–acetone, 8:1) to give (±)-**22** (80 mg, 31%) as a brown solid. M.p. 138–140 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.42 (s, 1H, NHCOOCH₃), 6.40 (s, 1H, 6'-H_{Ar}), 6.07–6.02 (m, 2H, CH=CH), 5.98 (s, 2H, OCH₂O), 4.99–4.95 (m, 1H, CHNHCOOCH₃), 4.45 (m, 1H, CHOH), 4.10 (s, 1H, OH), 3.96 (s, 3H, 7'-OCH₃), 3.94 (s, 3H, 4'-OCH₃), 3.14–3.10 (m, 1H, 6-CH), 2.30–2.10 (m, 2H, 5-CH₂), 1.93 (s, 3H, NHCOOCH₃); ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 172.2 (NHCOOCH₃) 142.0 (3'-a-C_{Ar}), 140.0 (7'-C_{Ar}), 138.5 (4'-C_{Ar}), 138.2 (7'a-C_{Ar}), 134.5 (CH=CHCO), 130.6 (5'-C_{Ar}), 127.2 (CH=CHCO), 105.1 (6'-CH_{Ar}), 101.6 (OCH₂O), 65.6 (CHOH), 60.6 (4'-OCH₃), 56.4 (7'-OCH₃), 50.0 (CHNHCOOCH₃), 37.4 (6-CH), 33.9 (5-CH₂), 22.8 (NHCOOCH₃); IR (KBr) 3344, 2952, 1685, 1538, 1506, 1455, 1433, 1140, 1060, 991, 803 cm⁻¹.

3 Results and discussion

3.1 Synthesis of apiolealdehyde (5)

At first, to achieve the selective monomethylation of a hydroxy group of compound **6**, it is necessary to block its two adjacent hydroxy ones. Although many reagents could be used for this purpose, such as phosgene [26], oxalyl chloride [27], diphenyldichloromethane [28, 29] or methylene iodide [30], their applications were not successful due to the low yield, the difficult removing the protective group or the very expensive reagent. However, using triethyl orthoformate [31], in the presence of a cation exchange resin (Amberlite® IR-120), in toluene resulted in methyl 2-ethoxy-7-hydroxybenzo[*d*][1,3]dioxole-5-carboxylate (**7**) in quantitative yield (Fig. 2). The forming ethanol was removed by azeotropic distillation (Dean–Stark apparatus) to make complete this equilibrium reaction.

Next, compound **7** can readily be methylated with methyl iodide, in the presence of K₂CO₃, in acetone to afford methyl 2-ethoxy-7-methoxybenzo[*d*][1,3]dioxole-5-carboxylate (**8**)




Fig. 2 A new synthesis of apiolealdehyde (**5**) starting from the readily available methyl gallate (**6**)

in excellent yield (98%). To remove the ethoxymethylene protecting group, compound **8** was easily hydrolysed with methanolic hydrochloric acid to obtain methyl 3,4-dihydroxy-5-methoxybenzoate (**9**) in very good yield (87%) after recrystallization. A special brominating agent, 1,3-dibromo-5,5-dimethylhydantoin (DBDMH) [32], was used to achieve selectively the corresponding 2-bromo derivative (methyl 2-bromo-3,4-dihydroxy-5-methoxybenzoate, **10**) in very good yield (92%). Then, the benzodioxole ring was formed with dibromomethane in DMF, in the presence of KF to afford methyl 4-bromo-7-methoxybenzo[*d*][1,3]dioxole-5-carboxylate (**11**) in good yield (75%).

After hydrolysing the methyl ester group of compound **11** using KOH in isopropyl alcohol and under reflux, the afforded bromo myristicin acid (4-bromo-7-methoxybenzo[*d*][1,3]dioxole-5-carboxylic acid, **12**) in 79% yield was reacted with NaOMe in methanolic solution by using Dallacker's method [22] to obtain apiolic acid (4,7-dimethoxybenzo[*d*][1,3]dioxole-5-carboxylic acid, **13**) in very good yield (82%). Then compound **13** was decarboxylated in *N,N*-dimethylaniline (DMA), under reflux applying Sato's modified method [33] to afford 4,7-dimethoxybenzo[*d*][1,3]dioxole (**14**) in moderate yield (46%) after vacuum distillation. Finally, the formylation of compound **14** was accomplished by using the Wilsmeier–Haack reaction [POCl₃, *N*-methylformanilide (NMFA)] to obtain compound **5** in good yield (59%) after column chromatography.

3.2 Stereoselective synthesis of a cyclic allyl alcohol derivative containing two methoxy groups [(±)-**22**]

From this step, we have adapted our previously developed methods for the stereoselective total syntheses of some phenanthridone alkaloids and their analogues [12–15]. At first, as shown in Fig. 3, apiolealdehyde (**5**) was reacted with nitromethane in acetic acid, in the presence of NH₄OAc to give 4,7-dimethoxy-5-(2-nitrovinyl)benzo[*d*][1,3]dioxole (**15**) in good yield (82%).

The first asymmetric centre of the title molecule was formed by Michael addition of acetone to compound **15** in DMSO, in the presence of L-proline to afford racemic (±)-4-(4',7'-dimethoxybenzo[*d*][1,3]dioxol-5'-yl)-5-nitropentan-2-one [(±)-**16**] in excellent yield (97%). Although the pure enantiomer of this organocatalyst was applied, no enantioselectivity was observed in this reaction. In the next step, the ring C was formed by the Claisen–Henry reaction using ethyl formate and dry NaOMe in anhydrous diethyl ether to afford (±)-3-(4',7'-dimethoxybenzo[*d*][1,3]dioxol-5'-yl)-5-hydroxy-4-nitrocyclohexan-1-one [(±)-**17**]

in a moderate yield (55%). Complete stereoselectivity was achieved in this cyclisation step which can be explained by the H-bond formation between the C-5 hydroxy and C-4 nitro groups, as observed by us previously [12–15].

Prior to the conversion of the nitro group into the amino one by catalytic hydrogenation, the carbonyl group of (±)-**17** was protected with ethylene glycol, in the presence of (COOH)₂, in anhydrous MeCN to afford (±)-9-(4',7'-dimethoxybenzo[*d*][1,3]dioxol-5'-yl)-8-nitro-1,4-dioxaspiro[4.5]decan-7-ol [(±)-**18**] in good yield (77%). Compound (±)-**18** was reduced to the corresponding amino derivative, such as (±)-8-amino-9-(4',7'-dimethoxybenzo[*d*][1,3]dioxol-5'-yl)-1,4-dioxaspiro[4.5]decan-7-ol [(±)-**19**] in excellent yield (95%) over a 10% Pd/C catalyst (Selcat Q [34]), in methanol, at 80 °C and 12 bar. Subsequently, the *N*-acylation of compound (±)-**19** by an activated ester [35] was carried out with methyl chloroformate in a biphasic solvent mixture (water and THF) to obtain (±)-7-(4',7'-dimethoxybenzo[*d*][1,3]dioxol-5'-yl)-9-hydroxy-1,4-dioxaspiro[4.5]decan-8-yl)carbamic acid methyl ester [(±)-**20**] in very good yield (86%). The ketal protective group of (±)-**20** was removed in acetone containing a catalytic amount of *p*-TsOH under reflux, but water elimination also took place to afford (±)-6-(4',7'-dimethoxybenzo[*d*][1,3]dioxol-5'-yl)-4-oxocyclohex-2-en-1-yl)carbamic acid methyl ester [(±)-**21**] in excellent yield (97%). Then, the oxo group of was stereoselectively reduced with NaBH₄, in the presence of CaCl₂ in abs. methanol (Utimoto's method [36]) to obtain (±)-6-(4',7'-dimethoxybenzo[*d*][1,3]dioxol-5'-yl)-4-hydroxycyclohex-2-en-1-yl)carbamic acid methyl ester [(±)-**22**] in moderate yield (31%) after preparative TLC. The stereoselectivity was presumably due to an axial attack of the small hydride ion derived from NaBH₄ enhanced by the coordination with Ca²⁺, resulting in an equatorial position of the newly formed hydroxy group.

This cyclic allyl alcohol derivative containing two methoxy groups [(±)-**22**] is a pivotal intermediate of our total synthesis to obtain a novel (±)-*trans*-dihydonarciclasine analogue [(±)-**23**] containing an additional methoxy group at position 11, in the ring A of the phenanthridone scaffold.

4 Conclusion

In summary, a pivotal intermediate [(±)-**22**] using for the synthesis of a new (±)-*trans*-dihydonarciclasine alkaloid analogue [(±)-**23**] was efficiently prepared from methyl gallate (**6**), an inexpensive and readily available starting material, in 17 steps with 0.9% overall yield applying a newly developed synthetic route.




Fig. 3 Stereoselective synthetic route of a novel (±)-*trans*-dihydronarciclasine analogue [(±)-23] containing an additional methoxy group in the ring A of the phenanthridone scaffold

References

- [1] Kornienko, A., Evidente, A. "Chemistry, Biology, and Medicinal Potential of Narciclasine and its Congeners", *Chemical Reviews*, 108(6), pp. 1982–2014, 2008.
<https://doi.org/10.1021/cr078198u>
- [2] Ceriotti, G. "Narciclasine: an Antimitotic Substance from *Narcissus* Bulbs", *Nature*, 213(5076), pp. 595–596, 1967.
<https://doi.org/10.1038/213595a0>
- [3] Okamoto, T., Torii, Y., Isogai, Y. "Lycoricidinol and Lycoricidine, New Plant-growth Regulators in the Bulbs of *Lycoris radiata* HERB.", *Chemical and Pharmaceutical Bulletin*, 16(9), pp. 1860–1864, 1968.
<https://doi.org/10.1248/cpb.16.1860>
- [4] Pettit, G. R., Cragg, M. G., Singh, S. B., Duke, A. J., Doubek, D. L. "Antineoplastic Agents, 162. *Zephyranthes candida*", *Journal of Natural Products*, 53(1), pp. 176–178, 1990.
<https://doi.org/10.1021/np50067a026>
- [5] Pettit, G. R., Gaddamidi, V., Herald, D. L., Singh, S. B., Cragg, G. M., Schmidt, J. M., Boettner, F. E., Williams, M., Sagawa, Y. "Antineoplastic Agents, 120. *Pancreatium littorale*", *Journal of Natural Products*, 49(6), pp. 995–1002, 1986.
<https://doi.org/10.1021/np50048a005>
- [6] Pettit, G. R., Pettit III, G. R., Backhaus, R. A., Boyd, M. R., Meerow, A. W. "Antineoplastic Agents, 256. Cell Growth Inhibitory Isocarboxystyryls from *Hymenocallis*", *Journal of Natural Products*, 56(10), pp. 1682–1687, 1993.
<https://doi.org/10.1021/np50100a004>
- [7] Rigby, J. H., Mateo, M. E. "Total Synthesis of (+)-Narciclasine", *Journal of the American Chemical Society*, 119(51), pp. 12655–12656, 1997.
<https://doi.org/10.1021/ja972950z>
- [8] Shin, I. J., Choi, E. S., Cho, C. G. "Total Synthesis of (±)-*trans*-Dihydronarciclasine through a Highly *endo*-Selective Diels–Alder Cycloaddition of 3,5-Dibromo-2-pyrone", *Angewandte Chemie International Edition*, 46(13), pp. 2303–2305, 2007.
<https://doi.org/10.1002/anie.200604612>
- [9] Danishefsky, S., Lee, J. Y. "Total Synthesis of (±)-Pancratistatin", *Journal of the American Chemical Society*, 111(13), pp. 4829–4837, 1989.
<https://doi.org/10.1021/ja00195a039>
- [10] Isobe, K., Taga, J., Tsuda, Y. "Syntheses of (±)-Dihydrolycoricidines from the Common Intermediate to Ethanophenanthridine Alkaloids", *Heterocycles*, 9(5), pp. 625–630, 1978.
<https://doi.org/10.3987/R-1978-05-0625>
- [11] Ghavre, M., Froese, J., Pour, M., Hudlicky, T. "Synthesis of Amaryllidaceae Constituents and Unnatural Derivatives", *Angewandte Chemie International Edition*, 55(19), pp. 5642–5691, 2016.
<https://doi.org/10.1002/anie.201508227>
- [12] Szántó, G., Hegedűs, L., Mattyasovszky, L., Simon, A., Simon, Á., Bitter, I., Tóth, G., Tőke, L., Kádas, I. "An expedient total synthesis of *ent*-(-)-7-deoxy-*trans*-dihydronarciclasine", *Tetrahedron*, 65(40), pp. 8412–8417, 2009.
<https://doi.org/10.1016/j.tet.2009.07.092>
- [13] Varró, G., Hegedűs, L., Simon, A., Balogh, A., Grün, A., Leveles, I., Vértessy, G. B., Kádas, I. "The First Enantioselective Total Synthesis of (-)-*trans*-Dihydronarciclasine", *Journal of Natural Products*, 80(6), pp. 1909–1917, 2017.
<https://doi.org/10.1021/acs.jnatprod.7b00208>
- [14] Varró, G., Pogrányi, B., Grün, A., Simon, A., Hegedűs, L., Kádas, I. "Stereoselective synthesis of *trans*-dihydronarciclasine derivatives containing a 1,4-benzodioxane moiety", *Monatshfte für Chemie – Chemical Monthly*, 149(12), pp. 2265–2285, 2018.
<https://doi.org/10.1007/s00706-018-2287-7>
- [15] Varró, G., Mattyasovszky, L., Grün, A., Simon, A., Hegedűs, L., Kádas, I. "Highly Stereoselective Synthesis of *trans*-Dihydronarciclasine Analogues", *Synthesis*, 50(3), pp. 625–643, 2018.
<https://doi.org/10.1055/s-0036-1591514>
- [16] Varró, G., Pálchuber, P., Pogrányi, B., Simon, A., Hegedűs, L., Kádas, I. "(±)-*trans*-Dihydronarciclasine and (±)-*trans*-dihydrolycoricidine analogues modified in their ring A: Evaluation of their anticancer activity and a SAR study", *European Journal of Medicinal Chemistry*, 173, pp. 76–89, 2019.
<https://doi.org/10.1016/j.ejmech.2019.04.010>
- [17] Fabinyi, R., Széki, T. "Über die Einwirkung von Organomagnesiumverbindungen auf Apiolaldehyd. Darstellung des Apiolaldehyds" (Impact of organomagnesium compounds on apiolealdehyde. Preparation of apiolealdehydes), *Berichte der Deutschen Chemischen Gesellschaft*, 50(2), pp. 1335–1339, 1917. (in German)
<https://doi.org/10.1002/cber.19170500233>
- [18] Percec, V., Bera, T. K., Glodde, M., Fu, Q., Balagurusamy, V. S. K., Heiney, P. A. "Hierarchical Self-Assembly, Coassembly, and Self-Organization of Novel Liquid Crystalline Lattices and Superlattices from a Twin-Tapered Dendritic Benzamide and Its Four-Cylinder-Bundle Supramolecular Polymer", *Chemistry – A European Journal*, 9(4), pp. 921–935, 2003.
<https://doi.org/10.1002/chem.200390114>
- [19] Pettit, G. R., Singh, S. B. "Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2", *Canadian Journal of Chemistry*, 65(10), pp. 2390–2396, 1987.
<https://doi.org/10.1139/v87-399>
- [20] Song, C., Zhao, P., Hu, Z., Shi, S., Cui, Y., Chang, J. "An improved method for the synthesis of γ -DDB", *Bioorganic & Medicinal Chemistry Letters*, 20(7), pp. 2297–2298, 2010.
<https://doi.org/10.1016/j.bmcl.2010.01.166>
- [21] Wu, W. L., Chen, S. E., Chang, W. L., Chen, C. F., Lee, A. R. "Synthesis and antihepatotoxicity of some Wuweizisu analogues", *European Journal of Medicinal Chemistry*, 27(4), pp. 353–358, 1992.
[https://doi.org/10.1016/0223-5234\(92\)90148-T](https://doi.org/10.1016/0223-5234(92)90148-T)
- [22] Dallacker, F., Gohlke, F. "Derivate des Methylenedioxybenzols, VIII Synthese der Apiol- und der 2-Methoxy-apiolsäure" (Methylenedioxybenzene derivatives, VIII Synthesis of apiole and 2-methoxyapioleic acid), *Justus Liebigs Annalen der Chemie*, 644(1), pp. 30–36, 1961. (in German)
<https://doi.org/10.1002/jlac.19616440104>

- [23] Rizzacasa, M. A., Sargent, M. V. "The structure and synthesis of nepenthone-A, a naphthoquinone from *Nepenthes rafflesiana*", Journal of the Chemical Society, Perkin Transactions 1, 1, pp. 2017–2022, 1987.
<https://doi.org/10.1039/P19870002017>
- [24] Newson, H. L., Wild, D. A., Yeung, S. Y., Skelton, B. W., Flematti, G. R., Allan, J. E., Piggott, M. J. "Access to 1,2,3,4-Tetraoxygenated Benzenes via a Double Baeyer–Villiger Reaction of Quinizarin Dimethyl Ether: Application to the Synthesis of Bioactive Natural Products from *Antrodia camphorata*", The Journal of Organic Chemistry, 81(8), pp. 3127–3135, 2016.
<https://doi.org/10.1021/acs.joc.5b02861>
- [25] Dallacker, F., Bernabei, D. "Derivate des Methylendioxybenzols, 22. Mitt.: Über die Synthese von Indolderivaten der Methylendioxybenzolreihe" (Methylenedioxybenzene derivatives, Part 22: Synthesis of indole derivatives of the methylenedioxybenzene series), Monatshefte für Chemie – Chemical Monthly, 98(3), pp. 785–797, 1967. (in German)
<https://doi.org/10.1007/BF00901383>
- [26] Fischer, E., Freudenberg, K. "Über das Tannin und die Synthese ähnlicher Stoffe. III. Hochmolekulare Verbindungen" (Tannin and the Synthesis of Similar Substances. III. Compounds of High Molecular Weight), Berichte der Deutschen Chemischen Gesellschaft, 46(1), pp. 1116–1138, 1913. (in German)
<https://doi.org/10.1002/cber.191304601149>
- [27] Marhold, A., Klauke, E. "Neue benzokondensierte, tetrachlorierte, heterocyclische verbindungen und ein verfahren zu ihrer herstellung" (New benzo-condensed, tetrachlorated, heterocyclic compounds and a method for their production), Germany, DE Patent, 3329126, 1985.
- [28] Bradley, W., Robinson, R., Schwarzenbach, G. "CVII.—A synthesis of pyrylium salts of anthocyanidin type. Part XIX. A synthesis of delphinidin chloride not involving a demethylation process, and syntheses of hirsutidin chloride and of delphinidin chloride 3'-methyl ether, possibly identical with petunidin chloride", Journal of the Chemical Society, pp. 793–817, 1930.
<https://doi.org/10.1039/JR9300000793>
- [29] Jurd, L. "Plant Polyphenols. VI. Experiments on the Synthesis of 3,3'- and 4,4'-Di-O-Methylellagic Acid", Journal of the American Chemical Society, 81(17), pp. 4606–4610, 1959.
<https://doi.org/10.1021/ja01526a039>
- [30] Keserü, G. M., Nógrádi, M., Kajtár-Peredy, M. "Synthesis of Garugamblin-2, a Macrocyclic Diarylheptanoid Constituent of *Garuga gamblei*", Liebigs Annalen der Chemie, 1994(4), pp. 361–364, 1994.
<https://doi.org/10.1002/jlac.199419940408>
- [31] Wu, G., Guo, H. F., Gao, K., Liu, Y. N., Bastow, K. F., Morris-Natschke, S. L., Lee, K. H., Xie, L. "Synthesis of unsymmetrical biphenyls as potent cytotoxic agents", Bioorganic & Medicinal Chemistry Letters, 18(19), pp. 5272–5276, 2008.
<https://doi.org/10.1016/j.bmcl.2008.08.050>
- [32] Alam, A., Takaguchi, Y., Ito, H., Yoshida, T., Tsuboi, S. "Multi-functionalization of gallic acid towards improved synthesis of α - and β -DDB", Tetrahedron, 61(7), pp. 1909–1918, 2005.
<https://doi.org/10.1016/j.tet.2004.11.083>
- [33] Sato, K., Inoue, S., Sato, H. "The Synthesis of 2,3-Dimethoxy-5-methyl-*p*-benzoquinone", Bulletin of the Chemical Society of Japan, 45(11), pp. 3455–3457, 1972.
<https://doi.org/10.1246/bcsj.45.3455>
- [34] Máthé, T., Tungler, A., Petró, J. "Process for the preparation of supported metal catalysts", USA, US Patent 4361500, 1982.
- [35] Szemes, J., Malta-Lakó, Á., Tóth, R. E., Poppe, L. "Diisopropyl Malonate as Acylating Agent in Kinetic Resolution of Chiral Amines with Lipase B from *Candida antarctica*", Periodica Polytechnica Chemical Engineering, 66(3), pp. 458–464, 2022.
<https://doi.org/10.3311/PPch.19521>
- [36] Fujii, H., Oshima, K., Utimoto, K. "A Facile and Selective 1,2-Reduction of Conjugated Ketones with NaBH_4 in the Presence of CaCl_2 ", Chemistry Letters, 20(10), pp. 1847–1848, 1991.
<https://doi.org/10.1246/cl.1991.1847>